- Home
- SKYE vs WETO Comparison
SKYE vs WETO Comparison
Compare SKYE & WETO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- WETO
- Stock Information
- Founded
- SKYE 2012
- WETO 2019
- Country
- SKYE United States
- WETO China
- Employees
- SKYE N/A
- WETO N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- WETO
- Sector
- SKYE Health Care
- WETO
- Exchange
- SKYE Nasdaq
- WETO NYSE
- Market Cap
- SKYE 80.7M
- WETO 88.0M
- IPO Year
- SKYE N/A
- WETO 2025
- Fundamental
- Price
- SKYE $2.30
- WETO $2.46
- Analyst Decision
- SKYE Buy
- WETO
- Analyst Count
- SKYE 6
- WETO 0
- Target Price
- SKYE $16.60
- WETO N/A
- AVG Volume (30 Days)
- SKYE 237.9K
- WETO 2.0M
- Earning Date
- SKYE 05-08-2025
- WETO 01-01-0001
- Dividend Yield
- SKYE N/A
- WETO N/A
- EPS Growth
- SKYE N/A
- WETO N/A
- EPS
- SKYE N/A
- WETO N/A
- Revenue
- SKYE N/A
- WETO $5,350,773.00
- Revenue This Year
- SKYE N/A
- WETO N/A
- Revenue Next Year
- SKYE N/A
- WETO N/A
- P/E Ratio
- SKYE N/A
- WETO N/A
- Revenue Growth
- SKYE N/A
- WETO N/A
- 52 Week Low
- SKYE $1.14
- WETO $1.50
- 52 Week High
- SKYE $12.11
- WETO $4.30
- Technical
- Relative Strength Index (RSI)
- SKYE 57.25
- WETO N/A
- Support Level
- SKYE $1.96
- WETO N/A
- Resistance Level
- SKYE $2.28
- WETO N/A
- Average True Range (ATR)
- SKYE 0.23
- WETO 0.00
- MACD
- SKYE 0.02
- WETO 0.00
- Stochastic Oscillator
- SKYE 86.89
- WETO 0.00
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About WETO WEBUS INTERNATIONAL LIMITED
Webus International Ltd operates on a business model of Mobility-as-a-Service to identify and solve inefficiencies associated with inflexible or low-quality public transportation and provide cost-efficient and customized mass transportation services under different scenarios with comprehensive digital platforms. It offers commute shuttle service, customized chartered bus service, packaged tour service and other service to customers.